Feb 24 2026 09:08 PM EST

Harmony Biosciences: When a Blockbuster Drug Meets Market Anxiety, the Numbers Blink

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) has been a rare disease specialist that investors once flocked to—but over the past five days, its share price has fallen by 27.2%. The drop isn’t just a number; it’s a signal. Harmony’s blockbuster ambitions for WAKIX are colliding with patent drama, regulatory friction, and sector-wide macro jitters—leaving Wall Street blinking at the metrics.

Blockbuster Numbers, but the Market Flinches

The numbers tell a story of growth. Q4 2025 revenue clocked in at $243.8 million, up 21% year-over-year. Full-year 2025 net product revenue soared to $868.5 million, marking a 22% increase from 2024. Net income for the year landed at $158.7 million, or $2.71 per diluted share. Cash reserves, as of December 31, 2025, stood at $882.5 million. Guidance for 2026 forecasts blockbuster territory with $1.0–$1.04 billion in net revenue. Yet, the stock is down 23.8% over three months and 29.0% in six months. Why?

Patent Shadows: Exclusivity Isn’t Forever

Harmony’s revenue depends heavily on WAKIX, and patents are the wall protecting those profits. Recent settlements with generic filers pushed potential competition back to January 2030, but bench trials and legal wrangling have spooked investors. Deutsche Bank cut its target to $31 from $47 after a Delaware bench trial suggested a credible threat to WAKIX exclusivity. Truist, too, flagged risk: a high likelihood of generic entry before 2029. For a company with 86.23% institutional ownership, even a hint of patent risk can trigger rapid exits.

FDA Friction and Pipeline Detours

Harmony’s pipeline is deep, but not immune to regulatory turbulence. The FDA approved WAKIX for cataplexy in pediatric narcolepsy on February 17, 2026—a win. Yet, a Refusal to File letter for pitolisant in idiopathic hypersomnia (IH) rattled confidence, and pipeline assets face lengthy trials. Pitolisant GR’s NDA is on track for Q2 2026, with a PDUFA in Q1 2027. EPX-100, acquired via Epygenix, is in Phase 3 for Dravet syndrome and Lennox-Gastaut syndrome, but topline data won’t arrive until 1H 2027. Investors, ever impatient, see clinical timelines as uncertainty, not opportunity.

Macro Headwinds: Pharma’s Regulatory Maze

The Inflation Reduction Act (IRA) looms over the sector, with drug price negotiations set to impact Medicare-covered drugs from 2026. Harmony’s revenue stream is exposed. Legislative changes, coupled with declining public market valuations for biotech, have soured sentiment—even as venture funding shows signs of life ($15.5 billion in early rounds, $7.6 billion in late rounds for 2024). Investors fear reimbursement risk and pricing pressure, not just for Harmony, but across the rare disease pharma landscape.

Institutional Confidence vs. Short Seller Grit

Despite 25.9% return on equity and 17.4% return on assets (TTM ending Q3 2025), Harmony faces strong short interest: 5.68 million shares, or 12.9% of float, with a short interest ratio of 10.4. The battle is fierce: major holders (BlackRock, Vanguard, Fmr Llc) have piled in, but shorts are betting on patent threats and sector malaise to win.

The Numbers Blink: Rare Disease, Rare Certainty

Harmony’s commercial execution is strong—gross profit margin sits at 77.7%, operating margin at 27.3%, and free cash flow to sales at 35.9% (TTM Q3 2025). But rare disease pharma is a sector of rare certainty. With pipeline catalysts distant, patent drama fresh, and macro headwinds intensifying, the market has blinked—sending Harmony’s share price down 21.4% over the past year. For investors, the metrics are clear. For Harmony, the challenge is to turn blockbuster promise into durable trust.